Rapid point of care tests to detect COVID-19

Rapid point of care tests to determine infection (Antigen-tests) and/or past infection (Antibody-tests) are urgently needed in the current COVID-19 pandemic. Supplies are running out for molecular diagnostics, resulting in undertesting and ongoing spread of the virus. Rapid point of care Antigen-tests and Antibody-tests can provide a major benefit, as they produce a result within 10-15 minutes. Furthermore, no specialised laboratories are needs, as testing can be on site. Ingenasa is a company that has the expertise on board to make the tests. Combined with the unique coronavirus cultures and human monoclonal antibody expertise at the Amsterdam UMC there is a public-private partnership that combines knowledge and materials to produce properly evaluated tests.